Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)

Olivia A. Stein¹, Jennifer Lee¹, Evelyne Vinet², Arielle Mendel³, Christian Pineau⁴, Leanne Mielczarek⁵ and Sasha Bernatsky², ¹Research Institute of the McGill University Health Centre, Montreal, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵Lupus Canada, Newmarket, Canada

Meeting: ACR Convergence 2025

Keywords: clinical trial, Qualitative Research, Systemic lupus erythematosus (SLE)

Session Information

Date: Monday, October 27, 2025

Title: (1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Our objective is to identify barriers and facilitators perceived by people with systemic lupus erythematosus (SLE) regarding participation in clinical trials for novel/advanced agents, such as cellular therapies.

Methods: Adults from our SLE research cohort were invited to participate in 1-hour virtual focus groups concerning their perspectives on clinical trials for novel/advanced SLE therapies. Sessions, facilitated by trained moderators using standardized questions, were recorded and transcribed. An inductive thematic analysis approach was used to code the data and generate themes/sub-themes.

Results: Nineteen patients participated in four focus groups (two in English, two in French). The mean age (range) was 50.0 (21-77) years and mean disease duration was 21.4 years. Most (90%) of participants were female and 79% (15/19) were White, with the remainder being Black, Asian, and Hispanic. Six major themes emerged: two barriers and four facilitators to trial participation. The first barrier was time and logistical constraints, such as employment and travel. The second was risk aversion, including subthemes of concerns of SLE flare, drug side effects and early-phase trials. Facilitators included receiving clear, detailed clinical trial information. Disease instability was another driver, making patients increasingly willing to accept elevated health risks, time commitment and/or logistical challenges. Desire to support the lupus community was also an important factor. Finally, access in clinical trials to mental health counsellors, peer support, and close medical follow-up were strong facilitators of participation.

Conclusion: We identified potential barriers and facilitators/driving factors for SLE patients regarding clinical trial participation, which are particularly relevant for novel/advanced agents like cellular therapies.

Disclosures: O. Stein: None; J. Lee: None; E. Vinet: None; A. Mendel: None; C. Pineau: None; L. Mielczarek: None; S. Bernatsky: None.

To cite this abstract in AMA style:

Stein O, Lee J, Vinet E, Mendel A, Pineau C, Mielczarek L, Bernatsky S. Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE) [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/perspectives-on-clinical-trial-participation-for-novel-advanced-therapies-a-focus-group-study-in-systemic-lupus-erythematosus-sle/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/perspectives-on-clinical-trial-participation-for-novel-advanced-therapies-a-focus-group-study-in-systemic-lupus-erythematosus-sle/